AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02311920
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00112346
Drug: Cetuximab + platinum + gemcitabine
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
Trial: NCT00112346
Drug: Platinum + Gemcitabine
RxNorm normalized name: platinum
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
Trial: NCT02168725
Drug: briciclib
RxNorm normalized name: Briciclib
DrugBank: Briciclib (DB12004)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00492765
Drug: Interferon-beta-1a
RxNorm normalized name: Interferon-beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage and frequency as per label
Trial: NCT02359201
Drug: V0018
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oromucosal - Single dose
Trial: NCT03179163
Drug: Captopril Pill
RxNorm normalized name: captopril Pill
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACEi+SH
Trial: NCT03179163
Drug: Enalapril Pill
RxNorm normalized name: enalapril Pill
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACEi
Trial: NCT03179163
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: diuretic
Trial: NCT00598624
Drug: Treosulfan IV
DrugBank: Treosulfan (DB11678)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
Trial: NCT04154150
Drug: Intravenous ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single subanesthetic infusion of ketamine (0.5mg/kg)
Trial: NCT02326025
Drug: Olaratumab
RxNorm normalized name: Olaratumab
DrugBank: Olaratumab (DB06043)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered IV
Trial: NCT00644384
Drug: acitretin
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00287859
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
Trial: NCT03653052
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
Trial: NCT01427842
Drug: DEVINE vancomycin regimen
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
Trial: NCT03236740
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
Trial: NCT02151760
Drug: 18F-DCFPyL
RxNorm normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00310791
Drug: Hormone replacement therapy (estrogen/progestin)
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)
Trial: NCT00310791
Drug: Dehydroepiandrosterone (DHEA)
RxNorm normalized name: DEHYDROEPIANDROSTERONE (DHEA) CAP/TAB
DrugBank: Prasterone (DB01708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg tablet, 1 daily
Trial: NCT00321737
Drug: Dexlansoprazole MR
RxNorm normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
Trial: NCT00321737
Drug: Dexlansoprazole MR
RxNorm normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole MR 60 mg, orally, once daily for up to six months.
Trial: NCT00280878
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00280878
Drug: vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00280878
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00280878
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02025751
Drug: Metoclopramide Nasal Spray
RxNorm normalized name: metoclopramide Nasal Spray
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
Trial: NCT03237533
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be applied locally on the lesion
Trial: NCT03097588
Drug: Netupitant
RxNorm normalized name: Netupitant
DrugBank: Netupitant (DB09048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg, Given PO, QD
Trial: NCT03097588
Drug: Palonosetron Hydrochloride
RxNorm normalized name: Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5 mg, Given PO, QD
Trial: NCT01709734
Drug: galeterone
RxNorm normalized name: Galeterone
DrugBank: Galeterone (DB12415)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02546843
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
Trial: NCT02546843
Drug: Cisatracurium
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisatracurium 0.15mg/kg intravenously
Trial: NCT02546843
Drug: Nonspecific Neuromuscular Blockade reversal
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
Trial: NCT02546843
Drug: Specific Neuromuscular Blockade reversal
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
Trial: NCT02546843
Drug: maintaining the depth of neuromuscular blockade - rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
Trial: NCT02546843
Drug: maintaining the depth of neuromuscular blockade - cisatracurium
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
Trial: NCT02940379
Drug: sotagliflozin (SAR439954)
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT02940379
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: HCl syrup~Route of administration: oral
Trial: NCT02940379
Drug: metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT00181220
Drug: valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02794857
Drug: NP001
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02624726
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
Trial: NCT02624726
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
Trial: NCT03828448
Drug: Ublituximab
RxNorm normalized name: Ublituximab
DrugBank: Ublituximab (DB11850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - anti-CD 20 monoclonal antibody administered via IV infusion
Trial: NCT03828448
Drug: Umbralisib
RxNorm normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: - PI3K Delta Inhibitor oral daily dose
Trial: NCT03431974
Drug: LD-Aminopterin oral capsule
RxNorm normalized name: aminopterin
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-folate treatment
Trial: NCT01631513
Drug: Nucynta ER
RxNorm normalized name: Nucynta ER
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 to 250 mg every 12 hours
Trial: NCT02499315
Drug: AMG 357
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
Trial: NCT02530931
Drug: Gadolinium
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diffusion of gadolinium for a population with Meniere's disease in order to develop an imaging disease screening test
Trial: NCT00399971
Drug: Ex vivo immunotherapy
RxNorm normalized name: Ex-vivo expanded placental adherent stromal cells
DrugBank: PLX-R18 (DB17989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusions, once a week, at least 6 to 12 months
Trial: NCT03421041
Drug: Dexamethasone Oral Tablet
RxNorm normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone Oral Tablet，0.75mg/tablet
Trial: NCT03944681
Drug: Droperidol Injectable Solution
RxNorm normalized name: droperidol Injection
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.
Trial: NCT00502801
Drug: doripenem
RxNorm normalized name: Doripenem
DrugBank: Doripenem (DB06211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
Trial: NCT00003972
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003972
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003972
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003972
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00003972
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003972
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00588640
Drug: d-Methadone
RxNorm normalized name: D-methadone
DrugBank: Dextromethadone (DB15198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 subjects to receive 40 mg d-Methadone twice a day
Trial: NCT00588640
Drug: D-methadone
RxNorm normalized name: D-methadone
DrugBank: Dextromethadone (DB15198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
Trial: NCT01859741
Drug: OMP-59R5
RxNorm normalized name: OMP-54F28
DrugBank: Ipafricept (DB15045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMP-59R5 administered intravenously
Trial: NCT00911807
Drug: Cerebrolysin + donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg.
Trial: NCT00911807
Drug: Cerebrolysin + placebo
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Placebo for donepezil was given PO once daily during the whole study duration (28 weeks).
Trial: NCT00911807
Drug: Donepezil + placebo
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg.
Trial: NCT03322384
Drug: epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat will be administered orally, in pill form, twice daily until disease progression.
Trial: NCT03322384
Drug: SD-101
RxNorm normalized name: Alphanine SD
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.
Trial: NCT01859741
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered intravenously
Trial: NCT01859741
Drug: Cisplatin or Carboplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered intravenously
Trial: NCT01524302
Drug: Ceftaroline
RxNorm normalized name: Ceftaroline
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg Q12h
Trial: NCT01524302
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 750 mg QD
Trial: NCT01955213
Drug: methylnaltrexone
RxNorm normalized name: Methylnaltrexone
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
Trial: NCT02497118
Drug: Endostatin
RxNorm normalized name: Endostatin
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostatin,7.5mg/m\^2,intravenous, d1-14;
Trial: NCT02497118
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vinorelbine,25mg/m\^2,intravenous, d1, d8;
Trial: NCT02497118
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin，75mg/m\^2 intravenous,divide into d1-3
Trial: NCT02551575
Drug: Treatment of TCM
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks.
Trial: NCT01618591
Drug: Single dose rifaximin 1650 mg
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Trial: NCT01583218
Drug: Betrixaban
RxNorm normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.~Enoxaparin Placebo: Once daily, 6-14 days
Trial: NCT01583218
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.~Betrixaban Placebo: once daily, 35 days
Trial: NCT03660436
Drug: BMS-986165
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03660436
Drug: MMF
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT01401049
Drug: Fospropofol
RxNorm normalized name: Fospropofol
DrugBank: Fospropofol (DB06716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
Trial: NCT01401049
Drug: Propofol/Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
Trial: NCT02435836
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01298401
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00231218
Drug: dietary supplement--echinacea, propolis, and vitamin c
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04232813
Drug: Promestriene Vaginal
RxNorm normalized name: promestriene Vaginal Cream
DrugBank: Promestriene (DB12487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To insert the cream the patient must use the applicator provided in the way explained in the prospectus.
Trial: NCT00050232
Drug: AVP-923
RxNorm normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01334710
Drug: Sorafenib and OSI-906
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
Trial: NCT00441350
Drug: OM 40
RxNorm normalized name: Aptiom 400mg Tablet
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
Trial: NCT02016261
Drug: Fluvoxamine
RxNorm normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg
Trial: NCT01618591
Drug: Single dose levofloxacin 500 mg
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Trial: NCT00093938
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00976092
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60 mg prasugrel as loading dose prior to PPCI
Trial: NCT00976092
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
Trial: NCT00391079
Drug: Sativex
RxNorm normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg.